Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients

Introduction The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren’s syndrome (pSS). Methods Seventy-five pSS patients...

Full description

Saved in:
Bibliographic Details
Published inClinical rheumatology Vol. 38; no. 5; pp. 1301 - 1307
Main Authors Maślińska, Maria, Mańczak, Małgorzata, Kwiatkowska, Brygida
Format Journal Article
LanguageEnglish
Published London Springer London 01.05.2019
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0770-3198
1434-9949
1434-9949
DOI10.1007/s10067-019-04438-z

Cover

Loading…
Abstract Introduction The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren’s syndrome (pSS). Methods Seventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p  < 0.05. The approval of the Bioethics Committee was obtained. Results Two subgroups I-RF(+) (61%) and II-RF(−) (39%) were established, with lower WBC ( p  = 0.012) and higher ESR ( p  = 0.016), gammaglobulin concentration ( p  = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p  < 0.003). RF correlated negatively with WBC (rho = − 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+. Conclusions RF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
AbstractList IntroductionThe rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren’s syndrome (pSS).MethodsSeventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p < 0.05. The approval of the Bioethics Committee was obtained.ResultsTwo subgroups I-RF(+) (61%) and II-RF(−) (39%) were established, with lower WBC (p = 0.012) and higher ESR (p = 0.016), gammaglobulin concentration (p = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p < 0.003). RF correlated negatively with WBC (rho = − 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+.ConclusionsRF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren's syndrome (pSS).INTRODUCTIONThe rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren's syndrome (pSS).Seventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p < 0.05. The approval of the Bioethics Committee was obtained.METHODSSeventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p < 0.05. The approval of the Bioethics Committee was obtained.Two subgroups I-RF(+) (61%) and II-RF(-) (39%) were established, with lower WBC (p = 0.012) and higher ESR (p = 0.016), gammaglobulin concentration (p = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p < 0.003). RF correlated negatively with WBC (rho = - 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+.RESULTSTwo subgroups I-RF(+) (61%) and II-RF(-) (39%) were established, with lower WBC (p = 0.012) and higher ESR (p = 0.016), gammaglobulin concentration (p = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p < 0.003). RF correlated negatively with WBC (rho = - 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+.RF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.CONCLUSIONSRF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren's syndrome (pSS). Seventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p < 0.05. The approval of the Bioethics Committee was obtained. Two subgroups I-RF(+) (61%) and II-RF(-) (39%) were established, with lower WBC (p = 0.012) and higher ESR (p = 0.016), gammaglobulin concentration (p = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p < 0.003). RF correlated negatively with WBC (rho = - 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+. RF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
Introduction The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the role of RF as an immunological and prognostic factor in the primary Sjögren’s syndrome (pSS). Methods Seventy-five pSS patients (mean age 50.03 ± 15.1), 65 (87%) females, and 10 (13%) males. WBC, CRP, RF, ESR, gammaglobulins, C4, C3 component of complement, cryoglobulins, ANA, anti-SS-A, and anti-SS-B antibodies were determined. The disease activity assessed with ESSDAI. Minor salivary gland biopsy (focus score and immunochemistry) was conducted. Results were analyzed with U Mann-Whitney (continuous variables) tests, correlations between quantitative variables assessed with the Spearman correlation coefficient with statistical significance set at p  < 0.05. The approval of the Bioethics Committee was obtained. Results Two subgroups I-RF(+) (61%) and II-RF(−) (39%) were established, with lower WBC ( p  = 0.012) and higher ESR ( p  = 0.016), gammaglobulin concentration ( p  = 0.007) in group I. Conjunctivitis sicca was more severe in group I. There was positive correlation between RF and lnANA (rho = 0.496), anti-SS-A, anti-SS-B antibodies (rho = 0.448; rho = 0.397 respectively). There was higher disease activity ESSDAI in group I than in group II (Me, 3.0 vs 2.0; p  < 0.003). RF correlated negatively with WBC (rho = − 0.374). RF did not correlate with serum concentrations of BAFF, APRIL, CRP, and C3, C4 and with CD19+, CD3+, CD4+, CD 21+, and CD35+. Conclusions RF should be considered as a prognostic, but not diagnostic, factor in patients with pSS, as it is associated with more severe disease course (sicca eye symptoms, ESSDAI) and parameters (production of gammaglobulins, ANA, anti SS-A, anti-SS-B autoantibodies) indicating increased B cell activity.
Author Kwiatkowska, Brygida
Maślińska, Maria
Mańczak, Małgorzata
Author_xml – sequence: 1
  givenname: Maria
  orcidid: 0000-0002-2211-0302
  surname: Maślińska
  fullname: Maślińska, Maria
  email: maslinskam@gmail.com
  organization: National Institute of Geriatrics, Rheumatology and Rehabilitation, Early Arthritis Clinic
– sequence: 2
  givenname: Małgorzata
  surname: Mańczak
  fullname: Mańczak, Małgorzata
  organization: Department of Gerontology and Public Health, National Institute of Geriatrics, Rheumatology and Rehabilitation
– sequence: 3
  givenname: Brygida
  surname: Kwiatkowska
  fullname: Kwiatkowska, Brygida
  organization: National Institute of Geriatrics, Rheumatology and Rehabilitation, Early Arthritis Clinic
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30810912$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9rHCEYxqWkNLvbfoEeipBLL5P6b2b0GEKaFAIpbHPoSRxHN25mdKvOIfvp42ayFHLIRfHl97w8j88SnPjgDQBfMTrHCLU_UjmbtkJYVIgxyqv9B7DAjLJKCCZOwAK1LaooFvwULFPaIoQIF_gTOKWIYyQwWYC_98nYafAmJRgsjA9mGlUOrodW6RwiVAkqD904Tj4MYeO0Gsqgh7sYNj6k7DQcVXw0EToPf6_XcKeyMz6nz-CjVUMyX17vFbj_efXn8qa6vbv-dXlxW2mGRa4EVj3RurGUMNTVvLaWNZ2yHe9tz-raakS6WrCatKIkIVZ3TadVpyk_PBVdge_z3uLo32RSlqNL2gyD8iZMSRLMm4ZQwXFBz96g2zBFX9zNFCWkJoX69kpN3Wh6uYuuJHySx08rAJ8BHUNK0VipXS6pg89RuUFiJA_9yLkfWfqRL_3IfZGSN9Lj9ndFdBalAvuNif9tv6N6Bqyoow4
CitedBy_id crossref_primary_10_1007_s10067_019_04540_2
crossref_primary_10_1016_j_trim_2021_101436
crossref_primary_10_20492_aeahtd_1035777
crossref_primary_10_1024_1661_8157_a003442
crossref_primary_10_1016_j_jns_2024_123215
crossref_primary_10_5114_reum_192613
crossref_primary_10_1515_cclm_2022_0244
crossref_primary_10_1111_cei_13508
crossref_primary_10_3390_jcm11010003
crossref_primary_10_1007_s10067_019_04869_8
crossref_primary_10_1111_1756_185X_14936
crossref_primary_10_1007_s00296_020_04782_3
crossref_primary_10_2147_JIR_S365326
crossref_primary_10_1016_j_ajo_2020_12_019
crossref_primary_10_1007_s10067_023_06818_y
crossref_primary_10_1016_j_autrev_2020_102686
crossref_primary_10_1136_ard_2023_223901
Cites_doi 10.1136/annrheumdis-2012-202293
10.1097/00005792-200207000-00004
10.1007/s002960050112
10.1007/s00296-009-0997-1
10.1016/j.bbrc.2009.09.012
10.1002/art.39518
10.1186/s12865-017-0234-8
10.1186/ar3348
10.1136/annrheumdis-2011-201117
10.1016/j.semarthrit.2012.11.007
10.1159/000066861
10.1186/ar4442
10.1136/bmj.e5244
10.1006/clim.2002.5210
10.1093/rheumatology/keu417
10.1016/j.jaut.2010.06.012
10.1002/acr.21591
10.1155/2013/726598
10.1136/bmj.e5841
10.1186/ar4152
10.1002/acr.23762
ContentType Journal Article
Copyright The Author(s) 2019
Clinical Rheumatology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2019
– notice: Clinical Rheumatology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s10067-019-04438-z
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Academic Middle East (New)
MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1434-9949
EndPage 1307
ExternalDocumentID 30810912
10_1007_s10067_019_04438_z
Genre Journal Article
GrantInformation_xml – fundername: National Institute of Geriatrics, Rheumatology and Rehabilitation
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-~C
.86
.VR
06C
06D
0R~
0VY
199
1N0
203
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2~H
30V
36B
4.4
406
408
409
40D
40E
5GY
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANZL
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABSXP
ABTEG
ABTKH
ABTMW
ABUWG
ABWNU
ABXPI
ACAOD
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFKRA
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CCPQU
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GXS
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KPH
LAS
LLZTM
M1P
M4Y
MA-
N9A
NB0
NPVJJ
NQJWS
NU0
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RNS
ROL
RPX
RRX
RSV
S16
S27
S37
S3B
SAP
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
VC2
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z91
ZMTXR
ZOVNA
~A9
~EX
~KM
-Y2
1SB
28-
2P1
2VQ
53G
5QI
AANXM
AAPKM
AARHV
AAYTO
AAYXX
ABBRH
ABDBE
ABFSG
ABQSL
ABULA
ACBXY
ACSTC
ACUDM
ADHKG
AEBTG
AEFIE
AEKMD
AEZWR
AFDZB
AFEXP
AFHIU
AFLOW
AFOHR
AGGDS
AGQPQ
AHPBZ
AHWEU
AIXLP
AJBLW
ATHPR
AYFIA
BBWZM
CAG
CITATION
COF
EN4
GRRUI
H13
KOW
N2Q
NDZJH
O9-
PHGZM
PHGZT
R4E
RIG
RNI
RZK
S1Z
S26
S28
SCLPG
SDE
T16
UZXMN
VFIZW
ZGI
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7XB
8FK
ABRTQ
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c419t-91ad2cc6f3240b585ff46bafb8dfd455fc02b59452791982fcb6bcabc381982a3
IEDL.DBID U2A
ISSN 0770-3198
1434-9949
IngestDate Fri Jul 11 05:41:09 EDT 2025
Fri Jul 25 07:05:48 EDT 2025
Thu Apr 03 06:56:33 EDT 2025
Tue Jul 01 04:05:09 EDT 2025
Thu Apr 24 22:55:44 EDT 2025
Fri Feb 21 02:38:52 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Prognostic factor
Rheumatoid factor
Sjögren’s syndrome
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c419t-91ad2cc6f3240b585ff46bafb8dfd455fc02b59452791982fcb6bcabc381982a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2211-0302
OpenAccessLink https://link.springer.com/10.1007/s10067-019-04438-z
PMID 30810912
PQID 2186632252
PQPubID 326351
PageCount 7
ParticipantIDs proquest_miscellaneous_2186623981
proquest_journals_2186632252
pubmed_primary_30810912
crossref_citationtrail_10_1007_s10067_019_04438_z
crossref_primary_10_1007_s10067_019_04438_z
springer_journals_10_1007_s10067_019_04438_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20190501
2019-5-00
2019-May
PublicationDateYYYYMMDD 2019-05-01
PublicationDate_xml – month: 5
  year: 2019
  text: 20190501
  day: 1
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: Germany
– name: Heidelberg
PublicationSubtitle Journal of the International League of Associations for Rheumatology
PublicationTitle Clinical rheumatology
PublicationTitleAbbrev Clin Rheumatol
PublicationTitleAlternate Clin Rheumatol
PublicationYear 2019
Publisher Springer London
Springer Nature B.V
Publisher_xml – name: Springer London
– name: Springer Nature B.V
References Cornec, Saraux, Pers, Jousse-Joulin, Marhadour, Roguedas-Contios, Genestet, Renaudineau, Devauchelle-Pensec (CR5) 2014; 16
Orge, Cefle, Yazici, Gürel-Polat, Hulagu (CR3) 2010; 30
Gottenberg, Cinquetti, Larroche (CR20) 2013; 72
Ingegnoli, Castelli, Gualtierotti (CR1) 2013; 35
Isaacs, Cohen, Emery, Tak, Wang, Lei, Williams, Lal, Read (CR23) 2013; 72
Ramos-Casals, Font, Garcia-Carrasco (CR14) 2002; 81
Nielsen, Bojeson, Schnohr, Nordestaarg (CR7) 2012; 345
Shiboski, Shiboski, Criswell (CR13) 2012; 64
Maneiro, Salgado, Carmona, Gomez-Reino (CR22) 2013; 43
Simard (CR8) 2012; 345
Nocturne, Virone, Ng, le Guern, Hachulla, Cornec, Daien, Vittecoq, Bienvenu, Marcelli, Wendling, Amoura, Dhote, Lavigne, Fior, Gottenberg, Seror, Mariette (CR16) 2016; 68
CR19
Youinou, Pers (CR11) 2011; 13
Jones, Shyu, Newkirk, Rigby (CR24) 2013; 15
Newkirk, Lepage, Niwa, Rubin (CR9) 1998; 44
Haberman, William, Euler, Shlomchik (CR2) 2003; 6
Mizuochi, Ito, Takai, Yamaguchi (CR6) 2009; 389
Flores-Chávez, Kostov, Solans (CR18) 2018; 36 Suppl 112
Sada, Isenberg, Ciurtin (CR21) 2015; 54
Watanabe, Gono, Nishina, Sugitani, Watanabe, Yabe, Terai (CR17) 2017; 18
Diaz-Lopez, Geli, Corominasetal (CR12) 2004; 31
Newkirk (CR4) 2002; 104
Witte, Hartung, Sachse (CR15) 2000; 19
Mavragani, Crow (CR10) 2010; 35
E Orge (4438_CR3) 2010; 30
M Ramos-Casals (4438_CR14) 2002; 81
MM Newkirk (4438_CR4) 2002; 104
MM Newkirk (4438_CR9) 1998; 44
T Witte (4438_CR15) 2000; 19
JD Isaacs (4438_CR23) 2013; 72
SC Shiboski (4438_CR13) 2012; 64
T Mizuochi (4438_CR6) 2009; 389
D Cornec (4438_CR5) 2014; 16
RJ Maneiro (4438_CR22) 2013; 43
G Nocturne (4438_CR16) 2016; 68
S Watanabe (4438_CR17) 2017; 18
JF Simard (4438_CR8) 2012; 345
JE Gottenberg (4438_CR20) 2013; 72
P Youinou (4438_CR11) 2011; 13
F Ingegnoli (4438_CR1) 2013; 35
CP Mavragani (4438_CR10) 2010; 35
AM Haberman (4438_CR2) 2003; 6
4438_CR19
SF Nielsen (4438_CR7) 2012; 345
C Diaz-Lopez (4438_CR12) 2004; 31
A Flores-Chávez (4438_CR18) 2018; 36 Suppl 112
PR Sada (4438_CR21) 2015; 54
JD Jones (4438_CR24) 2013; 15
References_xml – volume: 72
  start-page: 1026
  year: 2013
  end-page: 1031
  ident: CR20
  article-title: Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the Autoimmune and Rituximab registry
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-202293
– volume: 81
  start-page: 281
  year: 2002
  end-page: 292
  ident: CR14
  article-title: Primary Sjogren syndrome: hematologic patterns of disease expression
  publication-title: Medicine (Baltimore)
  doi: 10.1097/00005792-200207000-00004
– volume: 19
  start-page: 107
  year: 2000
  end-page: 111
  ident: CR15
  article-title: Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group
  publication-title: Rheumatol Int
  doi: 10.1007/s002960050112
– ident: CR19
– volume: 30
  start-page: 485
  issue: 4
  year: 2010
  end-page: 488
  ident: CR3
  article-title: The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-009-0997-1
– volume: 389
  start-page: 512
  issue: 3
  year: 2009
  end-page: 515
  ident: CR6
  article-title: Differential susceptibility of peripheral blood CD5+ and CD5- B cells to apoptosis in chronic hepatitis C patients
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.09.012
– volume: 36 Suppl 112
  start-page: 121
  issue: 3
  year: 2018
  end-page: 129
  ident: CR18
  article-title: Severe, life-threatening phenotype of primary Sjögren’s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry)
  publication-title: Clin Exp Rheumatol
– volume: 68
  start-page: 977
  year: 2016
  end-page: 985
  ident: CR16
  article-title: Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39518
– volume: 18
  start-page: 53
  year: 2017
  ident: CR17
  article-title: Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody- associated vasculitis
  publication-title: BMC Immunol
  doi: 10.1186/s12865-017-0234-8
– volume: 13
  start-page: 227
  year: 2011
  ident: CR11
  article-title: Disturbance of cytokine networks in Sjögren’s syndrome
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar3348
– volume: 72
  start-page: 329
  issue: 3
  year: 2013
  end-page: 336
  ident: CR23
  article-title: Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-201117
– volume: 43
  start-page: 9
  issue: 1
  year: 2013
  end-page: 17
  ident: CR22
  article-title: Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2012.11.007
– volume: 31
  start-page: 1352
  issue: 7
  year: 2004
  end-page: 1355
  ident: CR12
  article-title: Are there clinical or serological differences between male and female patients with primary Sjögren’s syndrome?
  publication-title: J Rheumatol
– volume: 6
  start-page: 169
  year: 2003
  end-page: 195
  ident: CR2
  article-title: Rheumatoid factors in health and disease: structure, function, induction and regulation
  publication-title: Curr Dir Autoimmun
  doi: 10.1159/000066861
– volume: 16
  start-page: R15
  year: 2014
  ident: CR5
  article-title: Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in primary Sjogren’s syndrome
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4442
– volume: 44
  start-page: 1129
  year: 1998
  end-page: 1138
  ident: CR9
  article-title: Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with Rheumatoid Arthritis (RA)
  publication-title: Cell Molec Biol
– volume: 345
  start-page: e5244
  year: 2012
  ident: CR7
  article-title: Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study
  publication-title: BMJ
  doi: 10.1136/bmj.e5244
– volume: 104
  start-page: 1
  year: 2002
  end-page: 13
  ident: CR4
  article-title: Rheumatoid factors: host resistance or autoimmunity?
  publication-title: Clin Immunol
  doi: 10.1006/clim.2002.5210
– volume: 54
  start-page: 219
  year: 2015
  end-page: 230
  ident: CR21
  article-title: Biologic treatment in Sjögren’s syndrome
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keu417
– volume: 35
  start-page: 225
  year: 2010
  end-page: 231
  ident: CR10
  article-title: Activation of the type I interferon pathway in primary Sjögren’s syndrome
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2010.06.012
– volume: 64
  start-page: 475
  year: 2012
  end-page: 487
  ident: CR13
  article-title: American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.21591
– volume: 35
  start-page: 727
  issue: 6
  year: 2013
  end-page: 734
  ident: CR1
  article-title: Rheumatoid factor: clinicla applications
  publication-title: Dis Markers
  doi: 10.1155/2013/726598
– volume: 345
  start-page: e5841
  year: 2012
  ident: CR8
  article-title: Rheumatoid factor positivity in the general population. Is unlikely to be discovered incidentally
  publication-title: BMJ
  doi: 10.1136/bmj.e5841
– volume: 15
  start-page: R20
  issue: 1
  year: 2013
  ident: CR24
  article-title: A rheumatoid factor paradox: inhibition of rituximab effector function
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4152
– volume: 13
  start-page: 227
  year: 2011
  ident: 4438_CR11
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar3348
– volume: 43
  start-page: 9
  issue: 1
  year: 2013
  ident: 4438_CR22
  publication-title: Semin Arthritis Rheum
  doi: 10.1016/j.semarthrit.2012.11.007
– volume: 35
  start-page: 727
  issue: 6
  year: 2013
  ident: 4438_CR1
  publication-title: Dis Markers
  doi: 10.1155/2013/726598
– volume: 15
  start-page: R20
  issue: 1
  year: 2013
  ident: 4438_CR24
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4152
– volume: 30
  start-page: 485
  issue: 4
  year: 2010
  ident: 4438_CR3
  publication-title: Rheumatol Int
  doi: 10.1007/s00296-009-0997-1
– volume: 72
  start-page: 1026
  year: 2013
  ident: 4438_CR20
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2012-202293
– volume: 345
  start-page: e5244
  year: 2012
  ident: 4438_CR7
  publication-title: BMJ
  doi: 10.1136/bmj.e5244
– volume: 31
  start-page: 1352
  issue: 7
  year: 2004
  ident: 4438_CR12
  publication-title: J Rheumatol
– volume: 16
  start-page: R15
  year: 2014
  ident: 4438_CR5
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4442
– volume: 72
  start-page: 329
  issue: 3
  year: 2013
  ident: 4438_CR23
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2011-201117
– volume: 104
  start-page: 1
  year: 2002
  ident: 4438_CR4
  publication-title: Clin Immunol
  doi: 10.1006/clim.2002.5210
– volume: 35
  start-page: 225
  year: 2010
  ident: 4438_CR10
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2010.06.012
– volume: 64
  start-page: 475
  year: 2012
  ident: 4438_CR13
  publication-title: Arthritis Care Res (Hoboken)
  doi: 10.1002/acr.21591
– volume: 389
  start-page: 512
  issue: 3
  year: 2009
  ident: 4438_CR6
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2009.09.012
– volume: 81
  start-page: 281
  year: 2002
  ident: 4438_CR14
  publication-title: Medicine (Baltimore)
  doi: 10.1097/00005792-200207000-00004
– volume: 36 Suppl 112
  start-page: 121
  issue: 3
  year: 2018
  ident: 4438_CR18
  publication-title: Clin Exp Rheumatol
– volume: 18
  start-page: 53
  year: 2017
  ident: 4438_CR17
  publication-title: BMC Immunol
  doi: 10.1186/s12865-017-0234-8
– volume: 54
  start-page: 219
  year: 2015
  ident: 4438_CR21
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keu417
– volume: 345
  start-page: e5841
  year: 2012
  ident: 4438_CR8
  publication-title: BMJ
  doi: 10.1136/bmj.e5841
– volume: 44
  start-page: 1129
  year: 1998
  ident: 4438_CR9
  publication-title: Cell Molec Biol
– volume: 19
  start-page: 107
  year: 2000
  ident: 4438_CR15
  publication-title: Rheumatol Int
  doi: 10.1007/s002960050112
– volume: 6
  start-page: 169
  year: 2003
  ident: 4438_CR2
  publication-title: Curr Dir Autoimmun
  doi: 10.1159/000066861
– volume: 68
  start-page: 977
  year: 2016
  ident: 4438_CR16
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39518
– ident: 4438_CR19
  doi: 10.1002/acr.23762
SSID ssj0002891
Score 2.3146293
Snippet Introduction The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study...
The rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study assesses the...
IntroductionThe rheumatoid factor (RF) is present in numerous autoimmune disorders, although its role in many of them remains a subject of research. The study...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1301
SubjectTerms Adult
Aged
Antibodies, Antinuclear - blood
APRIL protein
Autoantibodies
Autoimmune Collection 2018
Autoimmune diseases
Biomarkers - blood
Biopsy
BLyS protein
CD19 antigen
CD3 antigen
CD4 antigen
Complement component C3
Complement component C4
Conjunctivitis
Cryoglobulins
Female
Fluorescent Antibody Technique, Indirect
Humans
Immunology
Lymphocytes B
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article
Predictive Value of Tests
Rheumatoid factor
Rheumatoid Factor - blood
Rheumatology
Salivary gland
Salivary Glands, Minor - pathology
Sjogren's syndrome
Sjogren's Syndrome - diagnosis
Sjogren's Syndrome - pathology
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwEA86QXwRv51OieCbFrcuSdsnEXEMQRHmYD6VfOJgtnPdXvbXe9elGyLutU3acF-5y11-R8i1UUlbOCcCrR0PmNYCVCqGwLUZWSONiKwrC2RfRbfPngd84A_cCl9WWdnE0lCbXOMZ-R32ThIofeH9-DvArlGYXfUtNDbJFkKXYUlXNFgGXJhEKzvmRRHamiT2l2b81Tmw0xBIY2qAgdLPf29Mf7zNP5nScgPq7JFd7znShwWr98mGzQ7I9ovPjR-Sj35h3WyEpovmjk4-7Qy80Xxo6KKnDpUFlRkd4oWQyuLBA0OxRCvLEa-ZfmGxzoQOM_rW61GPuVockX7n6f2xG_jGCYFmrWQK1JYmBLI7RNtTEBA4x4SSTsXGGca5081Q8YTxMEqALKHTSigtlcbwLQ5l-5jUsjyzp4Ryw4VtS2eEUkzHLDZJaIyMW44rCE1knbQqqqXao4pjc4tRusJDRkqnQOm0pHQ6r5Ob5ZzxAlNj7ehGxYzU61eRrqShTq6Wr0EzMN0hM5vP_BiEN2zVycmCicvftcETAk8JZt9WXF19_P-1nK1fyznZCUuJwnrIBqlNJzN7AT7LVF2WgvkDVenn9A
  priority: 102
  providerName: ProQuest
Title Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients
URI https://link.springer.com/article/10.1007/s10067-019-04438-z
https://www.ncbi.nlm.nih.gov/pubmed/30810912
https://www.proquest.com/docview/2186632252
https://www.proquest.com/docview/2186623981
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1da9sw8OgHjL2MtftK1wYN9rYFGkWS7cckJC0tDWVdIH0y-qSBzh5x8tJf3ztHTlu6FfoksE6yudOd7nxfAN-dyXoqBNWxNsiOsFYhS6VouB4n3mmnEh_qANmJOp2Ks5mcxaSwqol2b1yStaR-lOyGkhVNX_qZL5BN77ZhV5Ltjqd4yvsb-ctjn7wkIQmTpTFV5t97PL2OnumYz_yj9bUzfg_vor7I-msC78GWL_bhzUX0iH-A62nlw-qWBBYrA1vc-BXqoOXcsXUnHaYrpgs2pzSQRs7hA8coMKsoqUoz-0MhOgs2L9jl1RWLlVarjzAdj34PTzuxXULHim62RBxrxxHZgWrsGTQDQhDK6GBSF5yQMthjbmQmJE8yRAsP1ihjtbFktKVc9z7BTlEW_gsw6aTyPR2cMkbYVKQu487ptBukQYNEt6DbYC23sZY4tbS4zR-qIBOmc8R0XmM6v2vBj82av-tKGi9CHzbEyCNXVTn1z1IkgXgLvm2mkR_IyaELX64iDBU17Lbg85qIm9f1UP9B_QhX_2yo-rD5_7_l4HXgX-Etr08YRUUews5ysfJHqLksTRu2k1nSht3-eDCY0HhyfT7CcTCaXP7C2aEatuvDfA9neuvj
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtNAcFRSCbhU5R0osEhwAotmvV7bB4R4tEppG1W0kdqT2aeIVOw2ToToR_UbmbHXiVBFb73au-vRvHbG8wJ4bXUeS-9lZIxPImGMRJHK0HHdTJ1VVqbONwmyIzkci2_HyfEKXHa1MJRW2enERlHbytA_8vc0O0kS9_GPZ-cRTY2i6Go3QqNli1335ze6bPWHna9I3zecb28dfRlGYapAZMQgnyEoynKEyVMrOo3WsvdCauV1Zr0VSeLNJtdJLhKe5uiRc2-01EZpQ75NxlWM596CVRGjK9OD1c9bo4PvC93Pw4y-NCXtlmehTCcU6-HNgK47BSMEqpmLf6_CK_btldhsc-Vtr8NasFXZp5a57sGKK-_D7f0QjX8AJ-Pa-fkpKUtWeTb96eZo_1YTy9opPkzVTJVsQiUonY7FB5ZRUlhZUYdo9ovSg6ZsUrKDw0MWurzWD2F8I0h9BL2yKt0TYIlNpIuVt1JrYTKR2Zxbq7KBTzQ6Q6oPgw5rhQl9zGmcxmmx7MBMmC4Q00WD6eKiD28Xe87aLh7Xrt7oiFEEia6LJf_14dXiNcoiBVhU6ap5WEMNFQd9eNwScfG5GG0vtM1w97uOqsvD_w_L0-theQl3hkf7e8Xezmj3GdzlDXdRNuYG9GbTuXuOFtNMvwhsyuDHTUvGX9YPJzg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1da9RAcKgVii_id0-rrqBPGtpsdjfJg4hYj9ZqKdSD8ynuJx5oUi93iP1p_jpnks0dUuxbX5PdzTBfO5P5AnjuTJmpEFRibZCJsFahSBXouO7l3mmnch-6BNljdTARH6ZyugF_hloYSqscdGKnqF1j6R_5Ls1OUsR9fDfEtIiT_fGbs58JTZCiSOswTqNnkSP_-xe6b-3rw32k9QvOx-8_vztI4oSBxIq0XCBY2nGEL1BbOoOWcwhCGR1M4YITUga7x40sheR5id45D9YoY7Wx5OcUXGd47jW4nmcyJRnLpytnjwJ43bS-PCc9VxaxYCeW7eEdgU48hSUEKpzzfy_FC5buhShtd_mNb8HNaLWytz2b3YYNX9-BrU8xLn8Xvkxaj_gitcmawObf_BIt4WbmWD_Ph-mW6ZrNqBhl0Lb4wDFKD6sb6hXNflCi0JzNanZyespiv9f2HkyuBKX3YbNuar8NTDqpfKaDU8YIW4jCldw5XaRBGnSL9AjSAWuVjR3NabDG92rdi5kwXSGmqw7T1fkIXq72nPX9PC5dvTMQo4qy3VZrThzBs9VrlEoKtejaN8u4hlorpiN40BNx9bkMrTC00nD3q4Gq68P_D8vDy2F5ClsoD9XHw-OjR3CDd8xFaZk7sLmYL_1jNJ0W5knHowy-XrVQ_AV30ioI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Usefulness+of+rheumatoid+factor+as+an+immunological+and+prognostic+marker+in+PSS+patients&rft.jtitle=Clinical+rheumatology&rft.au=Ma%C5%9Bli%C5%84ska%2C+Maria&rft.au=Ma%C5%84czak%2C+Ma%C5%82gorzata&rft.au=Kwiatkowska%2C+Brygida&rft.date=2019-05-01&rft.eissn=1434-9949&rft.volume=38&rft.issue=5&rft.spage=1301&rft_id=info:doi/10.1007%2Fs10067-019-04438-z&rft_id=info%3Apmid%2F30810912&rft.externalDocID=30810912
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0770-3198&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0770-3198&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0770-3198&client=summon